Ferric Carboxymaltose Injection [Ferinject]
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Coronary Syndromes (ACS)
Conditions
Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More)
Trial Timeline
Mar 5, 2026 → May 1, 2028
NCT ID
NCT07476859About Ferric Carboxymaltose Injection [Ferinject]
Ferric Carboxymaltose Injection [Ferinject] is a approved stage product being developed by AstraZeneca for Acute Coronary Syndromes (ACS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07476859. Target conditions include Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07476859 | Approved | Recruiting |
Competing Products
20 competing products in Acute Coronary Syndromes (ACS)